Hall Capital Management’s Thermo Fisher Scientific TMO Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $570K | Sell |
1,190
-79
| -6% | -$42.9K | 0.2% | 61 |
|
|
2025
Q4 | $735K | Sell |
1,269
-323
| -20% | -$183K | 0.28% | 58 |
|
|
2025
Q3 | $772K | Sell |
1,592
-3,297
| -67% | -$1.53M | 0.3% | 57 |
|
|
2025
Q2 | $1.98M | Sell |
4,889
-903
| -16% | -$378K | 0.84% | 41 |
|
|
2025
Q1 | $2.88M | Buy |
5,792
+294
| +5% | +$159K | 1.34% | 25 |
|
|
2024
Q4 | $2.86M | Buy |
+5,498
| New | +$3.02M | 1.33% | 23 |
|
|
2024
Q2 | $3.02M | Buy |
5,454
+233
| +4% | +$133K | 1.44% | 22 |
|
|
2024
Q1 | $3.03M | Buy |
5,221
+31
| +0.6% | +$17.4K | 1.5% | 23 |
|
|
2023
Q4 | $2.75M | Buy |
5,190
+198
| +4% | +$95.8K | 1.62% | 23 |
|
|
2023
Q3 | $2.53M | Buy |
4,992
+466
| +10% | +$248K | 1.62% | 23 |
|
|
2023
Q2 | $2.36M | Buy |
4,526
+51
| +1% | +$27.5K | 1.33% | 28 |
|
|
2023
Q1 | $2.58M | Sell |
4,475
-121
| -3% | -$68.2K | 1.53% | 25 |
|
|
2022
Q4 | $2.53M | Sell |
4,596
-18
| -0.4% | -$9.54K | 1.52% | 27 |
|
|
2022
Q3 | $2.34M | Sell |
4,614
-201
| -4% | -$112K | 1.56% | 27 |
|
|
2022
Q2 | $2.62M | Buy |
4,815
+82
| +2% | +$45.1K | 1.72% | 25 |
|
|
2022
Q1 | $2.8M | Buy |
4,733
+25
| +0.5% | +$14.4K | 1.64% | 22 |
|
|
2021
Q4 | $3.14M | Buy |
4,708
+229
| +5% | +$143K | 1.78% | 21 |
|
|
2021
Q3 | $2.56M | Buy |
4,479
+30
| +0.7% | +$16.5K | 1.63% | 22 |
|
|
2021
Q2 | $2.24M | Buy |
+4,449
| New | +$2.1M | 1.45% | 27 |
|
|
2020
Q4 | $2.69M | Buy |
5,769
+191
| +3% | +$89.6K | 1.94% | 19 |
|
|
2020
Q3 | $2.45M | Buy |
5,578
+332
| +6% | +$137K | 1.94% | 19 |
|
|
2020
Q2 | $1.9M | Buy |
5,246
+142
| +3% | +$47.6K | 1.6% | 23 |
|
|
2020
Q1 | $1.45M | Buy |
5,104
+264
| +5% | +$83.2K | 1.48% | 25 |
|
|
2019
Q4 | $1.57M | Buy |
4,840
+170
| +4% | +$51.5K | 1.28% | 29 |
|
|
2019
Q3 | $1.36M | Buy |
4,670
+195
| +4% | +$55.8K | 1.19% | 33 |
|
|
2019
Q2 | $1.31M | Buy |
4,475
+585
| +15% | +$161K | 1.12% | 34 |
|
|
2019
Q1 | $1.06M | Buy |
3,890
+320
| +9% | +$79.6K | 0.93% | 41 |
|
|
2018
Q4 | $799K | Sell |
3,570
-210
| -6% | -$49.3K | 0.79% | 44 |
|
|
2018
Q3 | $923K | Buy |
3,780
+220
| +6% | +$50.6K | 0.8% | 44 |
|
|
2018
Q2 | $737K | Hold |
3,560
| – | – | 0.69% | 48 |
|
|
2018
Q1 | $735K | Sell |
3,560
-100
| -3% | -$21K | 0.71% | 46 |
|
|
2017
Q4 | $695K | Hold |
3,660
| – | – | 0.61% | 49 |
|
|
2017
Q3 | $692K | Sell |
3,660
-173
| -5% | -$31.3K | 0.64% | 49 |
|
|
2017
Q2 | $669K | Sell |
3,833
-25
| -0.6% | -$4.2K | 0.63% | 49 |
|
|
2017
Q1 | $593K | Sell |
3,858
-200
| -5% | -$30.6K | 0.56% | 53 |
|
|
2016
Q4 | $572K | Buy |
+4,058
| New | +$598K | 0.56% | 54 |
|
|
2015
Q3 | $480K | Buy |
3,933
+112
| +3% | +$14.6K | 0.57% | 51 |
|
|
2015
Q2 | $495K | Sell |
3,821
-100
| -3% | -$13K | 0.56% | 52 |
|
|
2015
Q1 | $526K | Sell |
3,921
-50
| -1% | -$6.45K | 0.55% | 53 |
|
|
2014
Q4 | $497K | Buy |
+3,971
| New | +$483K | 0.51% | 56 |
|
Other funds holding TMO
VCM
Hall Capital Management's TMO Position: Q1 2026 in Review
Hall Capital Management reduced its Thermo Fisher Scientific (TMO) stake by 6.2% in Q1 2026, selling an estimated $42.9K and leaving 1,190 shares worth $570K. The position accounts for 0.2% of the portfolio, ranked #61.
Hall Capital Management first reported a position in TMO in Q4 2014 and has held it in 40 quarters since. The position peaked at $3.14M in Q4 2021. 2,590 funds tracked by Wall St. Rank hold TMO as of Q1 2026.
- Hall Capital Management held 1,190 shares of Thermo Fisher Scientific worth $570K as of Q1 2026.
- Hall Capital Management sold 79 Thermo Fisher Scientific shares in Q1 2026, an estimated $42.9K.
- Thermo Fisher Scientific made up 0.2% of Hall Capital Management's portfolio in Q1 2026, its #61 holding.
- Hall Capital Management first reported a position in Thermo Fisher Scientific in Q4 2014 and has held it in 40 quarters since.
- Hall Capital Management's Thermo Fisher Scientific position peaked at $3.14M in Q4 2021.
- 2,590 funds tracked by Wall St. Rank held Thermo Fisher Scientific as of Q1 2026.
Based on Hall Capital Management's 13F filing for Q1 2026, filed 11 May 2026.